Author

Gareth Tomlinson

Observed names: G. Tomlinson, Gareth H. Tomlinson

Institution: Taiho Oncology (United States)

Observed institutions: Taiho Oncology (United States), Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh

ORCID: 0009-0002-7731-8829

Observed ORCID: 0009-0002-7731-8829

OpenAlex ID: A5058426048

Neutrophil-derived alpha defensins control inflammation by inhibiting macrophage mRNA translation

2016 · Matthew Brook, Gareth H. Tomlinson, et al. · Proceedings of the National Academy of Sciences · 86

Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study.

2022 · Vadim S Koshkin, Guru P. Sonpavde, et al. · Journal of Clinical Oncology · 19

1965MO Phase II study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety

2024 · V.S. Koshkin, P. Barthelemy, et al. · Annals of Oncology · 7

A phase I, open‐label, single‐dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib

2023 · Ling Gao, Ikuo Yamamiya, et al. · Clinical and Translational Science · 6

Abstract RF01-04: Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification

2024 · Senthil Damodaran, Fabrice André, et al. · Cancer Research · 5

Abstract P1-18-35: Futibatinib in combination with fulvestrant in patients with metastatic breast cancer (MBC) harboring high-level FGFR1 amplification: Preliminary data from a phase 2 study

2022 · Senthil Damodaran, Nisha Unni, et al. · Cancer Research · 3

Abstract PO4-06-07: Efficacy and safety of futibatinib in patients with locally advanced/metastatic triple-negative breast cancer harboring FGFR2 gene amplification: final results from the phase 2, open-label FOENIX-MBC2 study

2024 · Antonio Giordano, Nisha Unni, et al. · Cancer Research · 1

Abstract CT192: Phase 1, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib in adult subjects

2023 · Ling Gao, Ikuo Yamamiya, et al. · Cancer Research

A phase 2 study of futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC)

2021 · G. Sonpavde, V.S. Koshkin, et al. · European Urology Open Science

Anti-inflammatory mechanisms of the neutrophilreleased antimicrobial peptide α-defensins

2014 · Gareth Tomlinson · ERA

Works count: 10

Citation count: 127

H-index: 5

I10-index: 2